Table 4.
Treatment effects on the participants in both BSCTa (n=167) and F2Fb treatment (n=177) groups at 3, 5 or 6, 9, and 15 months after the start of treatment.
| Outcome | 3 months | 5 or 6 months | 9 months | 15 months | |
| Cotinine-validated point prevalence abstinence | |||||
|
|
F2F treatment, n (%) | 31 (17.5) | —c | — | 10 (5.7) |
|
|
BSCT, n (%) | 8 (4.8) | — | — | 7 (4.2) |
|
|
Percentage points, difference (95% CI) | 12.7 (6.2 to 19.4) | — | — | 1.5 (−3.5 to 6.4) |
| COd-validated point prevalence abstinence | |||||
|
|
F2F treatment, n (%) | 50 (28.2) | 31 (17.5) | — | 13 (7.3) |
|
|
BSCT, n (%) | 43 (25.7) | 23 (13.8) | — | 11 (6.6) |
|
|
Percentage points, difference (95% CI) | 2.5 (−6.9 to 11.8) | 3.7 (−4.0 to 11.4) | — | 0.7 (−4.9 to 6.7) |
| Self-reported point prevalence abstinencee | |||||
|
|
F2F treatment, n (%) | 35 (19.8) | 48 (27.1) | 39 (22) | 26 (14.7) |
|
|
BSCT, n (%) | 22 (13.2) | 13 (7.8) | 19 (11.4) | 5 (3) |
|
|
Percentage points, difference (95% CI) | 6.6 (−1.3 to 14.4) | 19.3 (11.5 to 27.0) | 10.7 (2.8 to 18.4) | 11.7 (5.8 to 17.9) |
| Self-reported continuous abstinencef | |||||
|
|
F2F treatment, n (%) | 30 (16.9) | 35 (19.8) | 23 (13) | 20 (11.3) |
|
|
BSCT, n (%) | 19 (11.4) | 10 (6) | 13 (7.8) | 3 (1.8) |
|
|
Percentage points, difference (95% CI) | 5.6 (−1.9 to 13.0) | 13.8 (6.8 to 20.8) | 5.2 (−1.4 to 11.8) | 9.5 (4.4 to 15.1) |
aBSCT: blended smoking cessation treatment.
bF2F: face-to-face.
cData not available.
dCO: carbon monoxide.
eAnswer “no” to the questionnaire question “Have you smoked one or more cigarettes (bags, cigars, pipe) in the last 7 days?”
fAnswer “no” to the questionnaire question “Have you smoked since the stop?”